ArticleDrug design, development and therapy2025
Dose-Response Analysis of Nalbuphine for Alleviating Catheter-Related Bladder Discomfort After Ureteroscopic Lithotripsy in Men: A Retrospective Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors associated with catheter-related bladder discomfort and its correlation with urinary catheter-related pain after minimally invasive urological surgery: a retrospective cohort study.Perioperative medicine (London, England) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to determine the median effective dose (ED50) and effective dose 95% (ED95) of nalbuphine for alleviating moderate-severe catheter-related bladder discomfort (CRBD) after ureteroscopic lithotripsy (URL) in male patients using probit regression analysis. Patients and Methods: This retrospective study analyzed anesthesia records of all male patients who underwent URL and received nalbuphine under general anesthesia at Jiaxing University Affiliated Hospital between August 2023 and August 2024. Patients were categorized into four groups based on nalbuphine dosage: 0.025, 0.05, 0.075, and 0.10 mg/kg. Data on patient demographics, CRBD scores, agitation scores, the Ramsay sedation scale, and urinary catheter-related pain (UCRP) scores were collected 5 min after laryngeal mask removal. Hemodynamic parameters, including mean blood pressure, heart rate (HR), and oxygen saturation (SPO Results: Data from 76 anesthesia records were retrieved. CRBD, agitation, and UCRP scores decreased with increasing nalbuphine doses, while the Ramsay sedation scores increased. No significant differences were observed in hemodynamic parameters across dose groups at any time point (P > 0.05). Similarly, the incidence of adverse effects did not differ significantly among the groups (P > 0.05). Probit regression analysis revealed that the ED50 of nalbuphine for alleviating moderate-severe CRBD following URL in male patients was 0.03 mg/kg (95% confidence interval [CI]: 0.013-0.046), while the ED95 was 0.108 mg/kg (95% CI: 0.085-0.188). Conclusion: Nalbuphine is a safe and effective agent for mitigating CRBD, with an ED50 of 0.03 mg/kg and ED95 of 0.108 mg/kg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.